Tecentriq

Medicinal product

(Invented) name

Tecentriq

Active substance (s)

Atezolizumabas

Strength

840 mg

Pharmaceutical form

koncentratas infuziniam tirpalui

Route (s) of administration

leisti į veną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

L01FF05, Atezolizumab

Marketing authorisation holder

Roche Registration GmbH, Vokietija

Date of authorisation

2017-09-21

Date of renewal

Documents

Tecentriq paciento kortele.pdf

Search in EMA Europe

Stage

Registruotas

Controlled?

No

Controlled substance type

Legal basis

8(3)

Procedure number

Marketing authorisation procedure

Centrinė registracija

Qualitative and quantitative composition

Concentrate for solution for infusion	14 ml
Atezolizumabas	840 mg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
102328	88428	1088428	flakonas	14 ml N1		Receptinis	EU/1/17/1220/002	Tiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2017-09-21	Registruotas